Abstract
Purpose: To describe the functional phenotypic features of East Asian patients with RP1L1-associated occult macular dystrophy (ie, Miyake disease). Design: An international multicenter retrospective cohort study. Methods: Twenty-eight participants (53 eyes) with Miyake disease were enrolled at 3 centers (in Japan, China, and South Korea). Ophthalmologic examinations including spectral-domain optical coherence tomography (SDOCT) and multifocal electroretinogram (mfERG) were performed. Patients were classified into 3 functional groups based on mfERG: Group 1, paracentral dysfunction with relatively preserved central/peripheral function; Group 2, homogeneous central dysfunction with preserved peripheral function; and Group 3, widespread dysfunction over the recorded area. Three functional phenotypes were compared in clinical parameters and SDOCT morphologic classification (severe phenotype, blurred/flat ellipsoid zone and absence of the interdigitation zone; mild phenotype, preserved ellipsoid zone). Results: There were 8 eyes in Group 1, 40 eyes in Group 2, and 5 eyes in Group 3. The patients in Group 1 showed significantly later onset (P =.005) and shorter disease duration (P =.002), compared with those in Group 2. All 8 eyes in Group 1 showed the mild morphologic phenotype, while 43 of 45 eyes in Groups 2 and 3 presented the severe phenotype, which identified a significant association between the functional grouping and the morphologic classification (P <.001). Conclusions: A spectrum of functional phenotypes of Miyake disease was first documented with identification of 3 functional subtypes. Patients with paracentral dysfunction had the mildest phenotype, and those with homogeneous central or widespread dysfunction showed overlapping clinical findings with severe photoreceptor changes, suggesting various extents of visual impairment.
Original language | English |
---|---|
Pages (from-to) | 169-180 |
Number of pages | 12 |
Journal | American Journal of Ophthalmology |
Volume | 221 |
DOIs | |
Publication status | Published - 2021 Jan |
ASJC Scopus subject areas
- Ophthalmology
Access to Document
Other files and links
Fingerprint
Dive into the research topics of 'Spatial Functional Characteristics of East Asian Patients With Occult Macular Dystrophy (Miyake Disease); EAOMD Report No. 2'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: American Journal of Ophthalmology, Vol. 221, 01.2021, p. 169-180.
Research output: Contribution to journal › Article › peer-review
}
TY - JOUR
T1 - Spatial Functional Characteristics of East Asian Patients With Occult Macular Dystrophy (Miyake Disease); EAOMD Report No. 2
AU - East Asia Inherited Retinal Disease Society Study Group
AU - Yang, Lizhu
AU - Joo, Kwangsic
AU - Tsunoda, Kazushige
AU - Kondo, Mineo
AU - Fujinami-Yokokawa, Yu
AU - Arno, Gavin
AU - Pontikos, Nikolas
AU - Liu, Xiao
AU - Nakamura, Natsuko
AU - Kurihara, Toshihide
AU - Tsubota, Kazuo
AU - Iwata, Takeshi
AU - Li, Hui
AU - Zou, Xuan
AU - Wu, Shijing
AU - Sun, Zixi
AU - Ahn, Seong Joon
AU - Kim, Min Seok
AU - Mun, Yong Seok
AU - Park, Kyu Hyung
AU - Robson, Anthony G.
AU - Miyake, Yozo
AU - Woo, Se Joon
AU - Sui, Ruifang
AU - Fujinami, Kaoru
N1 - Funding Information: Funding/Support: The EAOMD studies are supported by a Grant-in-Aid for Young Scientists (A) of the Ministry of Education, Culture, Sports, Science and Technology , Japan ( 16H06269 ); and Grant-in-Aid for Scientists to support international collaborative studies of the Ministry of Education, Culture, Sports, Science and Technology , Japan ( 16KK01930002 ). The authors also indicate the following support: Kazushige Tsunoda: Support–Japan Agency for Medical Research and Development, the Ministry of Health, Labor and Welfare, Japan (18ek0109282h0002); Grants–for Scientific Research, Japan Society for the Promotion of Science , Japan ( H26-26462674 ). Yu Fujinami-Yokokawa: Grants–Grant-in-Aid for Young Scientists of the Ministry of Education, Culture, Sports, Science and Technology , Japan ( 18K16943 ). Gavin Arno: Support–Fight for Sight (UK) Early Career Investigator award, NIHR-BRC at Moorfields Eye Hospital and the UCL Institute of Ophthalmology, and Great Britain Sasakawa Foundation Butterfield Award, UK. Anthony G. Robson: Support–is supported by the NIHR Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology and by the Moorfields Eye Charity. Toshihide Kurihara: Support–Tsubota Laboratory, Inc, Fuji Xerox Co, Ltd, Kirin Company, Ltd, Kowa Company, Ltd, Novartis Pharmaceuticals, Santen Pharmaceutical Co, Ltd, ROHTO Pharmaceutical Co, Ltd. Takeshi Iwata: Support–AMED (18ek0109282h0002). Se Joon Woo: Grants–Seoul National University Bundang Hospital (16-2019-003), National Research Foundation of Korea grant 2016R1D1A1B03934724 , funded by the Korean government (Ministry of Science, ICT and Future Planning [MSIP]). Ruifang Sui: Grants–Foundation Fighting Blindness (CD-CL-0214-0631-PUMCH); CAMS Innovation Fund for Medical Sciences, China, CIFMS 2016-12M-1-002; National Natural Science Foundation of China, China, 81873687. Kaoru Fujinami: Grants - Grant-in-Aid for Young Scientists (A) of the Ministry of Education, Culture, Sports, Science and Technology , Japan ( 16H06269 ); Grant-in-Aid for Scientists to support international collaborative studies of the Ministry of Education, Culture, Sports, Science and Technology , Japan ( 16KK01930002 ); National Hospital Organization Network Research Fund, Japan (H30-NHO-Sensory Organs-03); AMED (18ek0109355h0001); Foundation Fighting Blindness Alan Laties Career Development Program (CF-CL-0416-0696-UCL), USA; Health Labour Sciences Research Grant, The Ministry of Health Labour and Welfare, Japan (201711107A); Great Britain Sasakawa Foundation Butterfield Awards, UK. Role of the Funder/Sponsor: the sponsor or funding organization had no role in the design or conduct of this research. Financial Disclosures: The individual investigators who participate in the sponsored project(s) are not directly compensated by the sponsor but may receive salary or other support from the institution to support their effort on the project(s). Kaoru Fujinami has the following disclosures: Paid consultant–Astellas Pharma Inc, Kubota Pharmaceutical Holdings Co, Ltd, Acucela Inc, Novartis AG, Janssen Pharmaceutica, Sanofi Genzyme, NightstaRx Limited; Personal fees–Astellas Pharma Inc, Kubota Pharmaceutical Holdings Co, Ltd, Acucela Inc, Novartis AG, Santen Company Limited, Foundation Fighting Blindness, Foundation Fighting Blindness Clinical Research Institute, Japanese Ophthalmology Society, Japan Retinitis Pigmentosa Society; Grants–Astellas Pharma Inc. (NCT03281005), outside the submitted work. Se Joon Woo has the following disclosures: Paid consultant–Samsung Bioepis Inc., Panolos Bioscience Inc., Novelty Nobility Inc.; Co-founder of Retimark Inc., outside the submitted work. The following authors have no financial disclosures: Lizhu Yang, Kwangsic Joo, Kazushige Tsunoda, Mineo Kondo, Yu Fujinami-Yokokawa, Gavin Arno, Nikolas Pontikos, Xiao Liu, Natsuko Nakamura, Toshihide Kurihara, Kazuo Tsubota, Takeshi Iwata, Hui Li, Xuan Zou, Shijing Wu, Zixi Sun, Seong Joon Ahn, Min Seok Kim, Yong Seok Mun, Kyu Hyung Park, Anthony G. Robson, Yozo Miyake, Ruifang Sui. All authors attest that they meet the current ICMJE criteria for authorship. Funding Information: Funding/Support: The EAOMD studies are supported by a Grant-in-Aid for Young Scientists (A) of the Ministry of Education, Culture, Sports, Science and Technology, Japan (16H06269); and Grant-in-Aid for Scientists to support international collaborative studies of the Ministry of Education, Culture, Sports, Science and Technology, Japan (16KK01930002). The authors also indicate the following support: Kazushige Tsunoda: Support–Japan Agency for Medical Research and Development, the Ministry of Health, Labor and Welfare, Japan (18ek0109282h0002); Grants–for Scientific Research, Japan Society for the Promotion of Science, Japan (H26-26462674). Yu Fujinami-Yokokawa: Grants–Grant-in-Aid for Young Scientists of the Ministry of Education, Culture, Sports, Science and Technology, Japan (18K16943). Gavin Arno: Support–Fight for Sight (UK) Early Career Investigator award, NIHR-BRC at Moorfields Eye Hospital and the UCL Institute of Ophthalmology, and Great Britain Sasakawa Foundation Butterfield Award, UK. Anthony G. Robson: Support–is supported by the NIHR Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology and by the Moorfields Eye Charity. Toshihide Kurihara: Support–Tsubota Laboratory, Inc, Fuji Xerox Co, Ltd, Kirin Company, Ltd, Kowa Company, Ltd, Novartis Pharmaceuticals, Santen Pharmaceutical Co, Ltd, ROHTO Pharmaceutical Co, Ltd. Takeshi Iwata: Support–AMED (18ek0109282h0002). Se Joon Woo: Grants–Seoul National University Bundang Hospital (16-2019-003), National Research Foundation of Korea grant 2016R1D1A1B03934724, funded by the Korean government (Ministry of Science, ICT and Future Planning [MSIP]). Ruifang Sui: Grants–Foundation Fighting Blindness (CD-CL-0214-0631-PUMCH); CAMS Innovation Fund for Medical Sciences, China, CIFMS 2016-12M-1-002; National Natural Science Foundation of China, China, 81873687. Kaoru Fujinami: Grants - Grant-in-Aid for Young Scientists (A) of the Ministry of Education, Culture, Sports, Science and Technology, Japan (16H06269); Grant-in-Aid for Scientists to support international collaborative studies of the Ministry of Education, Culture, Sports, Science and Technology, Japan (16KK01930002); National Hospital Organization Network Research Fund, Japan (H30-NHO-Sensory Organs-03); AMED (18ek0109355h0001); Foundation Fighting Blindness Alan Laties Career Development Program (CF-CL-0416-0696-UCL), USA; Health Labour Sciences Research Grant, The Ministry of Health Labour and Welfare, Japan (201711107A); Great Britain Sasakawa Foundation Butterfield Awards, UK. Role of the Funder/Sponsor: the sponsor or funding organization had no role in the design or conduct of this research. Financial Disclosures: The individual investigators who participate in the sponsored project(s) are not directly compensated by the sponsor but may receive salary or other support from the institution to support their effort on the project(s). Kaoru Fujinami has the following disclosures: Paid consultant–Astellas Pharma Inc, Kubota Pharmaceutical Holdings Co, Ltd, Acucela Inc, Novartis AG, Janssen Pharmaceutica, Sanofi Genzyme, NightstaRx Limited; Personal fees–Astellas Pharma Inc, Kubota Pharmaceutical Holdings Co, Ltd, Acucela Inc, Novartis AG, Santen Company Limited, Foundation Fighting Blindness, Foundation Fighting Blindness Clinical Research Institute, Japanese Ophthalmology Society, Japan Retinitis Pigmentosa Society; Grants–Astellas Pharma Inc. (NCT03281005), outside the submitted work. Se Joon Woo has the following disclosures: Paid consultant–Samsung Bioepis Inc. Panolos Bioscience Inc. Novelty Nobility Inc.; Co-founder of Retimark Inc. outside the submitted work. The following authors have no financial disclosures: Lizhu Yang, Kwangsic Joo, Kazushige Tsunoda, Mineo Kondo, Yu Fujinami-Yokokawa, Gavin Arno, Nikolas Pontikos, Xiao Liu, Natsuko Nakamura, Toshihide Kurihara, Kazuo Tsubota, Takeshi Iwata, Hui Li, Xuan Zou, Shijing Wu, Zixi Sun, Seong Joon Ahn, Min Seok Kim, Yong Seok Mun, Kyu Hyung Park, Anthony G. Robson, Yozo Miyake, Ruifang Sui. All authors attest that they meet the current ICMJE criteria for authorship. Acknowledgment: This international multicenter study conducted by the East Asia Inherited Retinal Disease Society has been performed in 3 countries: Japan, China, and South Korea. Owing to the private information protection laws in each country, some data (such as deep genetic data or detailed clinical data) are not allowed to be shared across borders. The 3 corresponding authors from each country therefore have full data access separately in their home countries and take responsibility for the integrity of the data and the accuracy of the data analysis. The private information protection laws of China, Korea, and Japan for bioresources do not allow us to present/publish the genetic/clinical data of patients from their own countries without the corresponding local author taking clear responsibility. Acknowledgment: The authors thank the patients and their families for the participation in this study, as well as all the collaborators of East Asia Inherited Retinal Disease Society (https://www.fujinamik.com/east-asia-inherited-retinal-disease) and Japan Eye Genetics Consortium (http://www.jegc.org/) for data collection. The East Asia Inherited Retinal Disease Society (EAIRDs) Study Group: The EAOMD study is supported by a contract from the EAIRDs. The EAIRDs Study Group members are as follows: Chair's Office: National Institute of Sensory Organs, Kaoru Fujinami, Se Joon Woo, Ruifang Sui, Shiying Li, Hyeong Gon Yu, Bo Lei, Qingjiong Zhang, Chan Choi Mun, Fred Chen, Takeshi Iwata, Kazushige Tsunoda, Yozo Miyake, Mineo Kondo, Kunihiko Akiyama, Gen Hanazono, Masaki Fukui, Yu Fujinami-Yokokawa, Takayuki Kinoshita, Tatsuo Matsunaga, Satomi Inoue, Kazuki Yamazawa, Yasuiro Yamada, Michel Michaelides, Gavin Arno, Nikolas Pontikos, Yasutaka Suzuki, Asako Ihama, Reina Akita, Jun Ohashi, Izumi Naka, Kazutoshi Yoshitake, Daisuke Mori, Toshihide Kurihara, Kazuo Tsubota, Hiroaki Miyata, Kei Shinoda, Atsushi Mizota, Natsuko Nakamura, Takaaki Hayashi, Kazuki Kuniyoshi, Shuhei Kameya, Yusuke Murakami, Kwangsic Joo, Min Seok Kim, Kyu Hyung Park, Seong Joon Ahn, Dae Joong Ma, Joo Yong Lee, Sang Jin Kim, Christopher Seungkyu Lee, Jinu Han, Hyewon Chung, Jeeyun Ahn, Min Sagong, Young-Hoon-Ohn, Dong Ho Park, You Na Kim, Jong Suk Lee, Sang Jun Park, Jun Young Park, Won Kyung Song, Tae Kwan Park, Baek-Lok Oh, Jong Young Lee, Lizhu Yang, Xuan Zou, Hui Li, Zhengqin Yin, Yong Liu, Xiaohong Meng, Xiao Liu, Yanling Long, Jiayun Ren, Hongxuan Lie, Gang Wang, Anthony G. Robson, Xuemin Jin, Kunpeng Xie, Ya Li, Chonglin Chen, Qingge Guo, Lin Yang, Ya You, Tin Aung, Graham E. Holder. Publisher Copyright: © 2020 The Authors
PY - 2021/1
Y1 - 2021/1
N2 - Purpose: To describe the functional phenotypic features of East Asian patients with RP1L1-associated occult macular dystrophy (ie, Miyake disease). Design: An international multicenter retrospective cohort study. Methods: Twenty-eight participants (53 eyes) with Miyake disease were enrolled at 3 centers (in Japan, China, and South Korea). Ophthalmologic examinations including spectral-domain optical coherence tomography (SDOCT) and multifocal electroretinogram (mfERG) were performed. Patients were classified into 3 functional groups based on mfERG: Group 1, paracentral dysfunction with relatively preserved central/peripheral function; Group 2, homogeneous central dysfunction with preserved peripheral function; and Group 3, widespread dysfunction over the recorded area. Three functional phenotypes were compared in clinical parameters and SDOCT morphologic classification (severe phenotype, blurred/flat ellipsoid zone and absence of the interdigitation zone; mild phenotype, preserved ellipsoid zone). Results: There were 8 eyes in Group 1, 40 eyes in Group 2, and 5 eyes in Group 3. The patients in Group 1 showed significantly later onset (P =.005) and shorter disease duration (P =.002), compared with those in Group 2. All 8 eyes in Group 1 showed the mild morphologic phenotype, while 43 of 45 eyes in Groups 2 and 3 presented the severe phenotype, which identified a significant association between the functional grouping and the morphologic classification (P <.001). Conclusions: A spectrum of functional phenotypes of Miyake disease was first documented with identification of 3 functional subtypes. Patients with paracentral dysfunction had the mildest phenotype, and those with homogeneous central or widespread dysfunction showed overlapping clinical findings with severe photoreceptor changes, suggesting various extents of visual impairment.
AB - Purpose: To describe the functional phenotypic features of East Asian patients with RP1L1-associated occult macular dystrophy (ie, Miyake disease). Design: An international multicenter retrospective cohort study. Methods: Twenty-eight participants (53 eyes) with Miyake disease were enrolled at 3 centers (in Japan, China, and South Korea). Ophthalmologic examinations including spectral-domain optical coherence tomography (SDOCT) and multifocal electroretinogram (mfERG) were performed. Patients were classified into 3 functional groups based on mfERG: Group 1, paracentral dysfunction with relatively preserved central/peripheral function; Group 2, homogeneous central dysfunction with preserved peripheral function; and Group 3, widespread dysfunction over the recorded area. Three functional phenotypes were compared in clinical parameters and SDOCT morphologic classification (severe phenotype, blurred/flat ellipsoid zone and absence of the interdigitation zone; mild phenotype, preserved ellipsoid zone). Results: There were 8 eyes in Group 1, 40 eyes in Group 2, and 5 eyes in Group 3. The patients in Group 1 showed significantly later onset (P =.005) and shorter disease duration (P =.002), compared with those in Group 2. All 8 eyes in Group 1 showed the mild morphologic phenotype, while 43 of 45 eyes in Groups 2 and 3 presented the severe phenotype, which identified a significant association between the functional grouping and the morphologic classification (P <.001). Conclusions: A spectrum of functional phenotypes of Miyake disease was first documented with identification of 3 functional subtypes. Patients with paracentral dysfunction had the mildest phenotype, and those with homogeneous central or widespread dysfunction showed overlapping clinical findings with severe photoreceptor changes, suggesting various extents of visual impairment.
UR - http://www.scopus.com/inward/record.url?scp=85093067229&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85093067229&partnerID=8YFLogxK
U2 - 10.1016/j.ajo.2020.07.025
DO - 10.1016/j.ajo.2020.07.025
M3 - Article
C2 - 32707201
AN - SCOPUS:85093067229
SN - 0002-9394
VL - 221
SP - 169
EP - 180
JO - American Journal of Ophthalmology
JF - American Journal of Ophthalmology
ER -